The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

RSV vaccines effective, but more people need to get them Date: October 28, 2024 Source: University of Rochester Medical Center Summary: Doctors detail what we learned after the first season ...

Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD.

But which ones should you get? This year marks the second season for the new respiratory syncytial virus vaccine (RSV) for grown-ups. While not everyone needs it, the evidence so far suggests that ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

such as lung or heart disease Adults who live in nursing homes Adults who got the RSV shot last year do not need to get it again this year; the vaccine is protective for at least two years.

Future Virology. 2014;9(8):753-767. CHF: Congestive heart failure; CLD: Chronic lung disease; F: Fusion; G: Glyco; GLA-SE: Glucopyranosyl lipid A-stable emulsion; GMT ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Clover Biopharmaceuticals announced promising results from its Phase I trial of the RSV vaccine candidate SCB-1019, demonstrating comparable immunogenicity to GSK’s AREXVY while showing ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines. In a recent commentary in The Lancet, Angela ...